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Inhaled corticosteroid (ICS) therapy such as fluticasone propionate (FP) is effective in moderate-to-severe asthma, 
but for patients on ICS who still experience symptoms, treatment guidelines recommend either increasing the dose 
of ICS or adding a long-acting &agonist such as salmeterol or formoterol. Several studies have now shown that 
adding salmeterol provides greater clinical benefit than increasing the dose of ICS, raising the question of whether 
salmeterol has an additive or complementary anti-inflammatory effect to that of ICS. 
Recent studies on bronchial biopsies and bronchoalveolar lavage from asthmatic patients treated with either 
salmeterol, FP or placebo in addition to low-dose ICS have demonstrated that addition of salmeterol produces 
independent or additional reductions in several pro-inflammatory ceils, cytokines and cell adhesion molecules 
compared with FP. Such complementary anti-inflammatory effects may explain the improved control of asthma 
symptoms and exacerbations observed when salmeterol is added to low-dose ICS therapy, and may help to modify 
the long-term sequelae of asthma. These findings also indicate, contrary to earlier speculation, that salmeterol does 
not have a pro-inflammatory effect or mask persistent airway inflammation. 
This review presents the results of recent studies and suggests possible mechanisms for the additional anti- 
inflammatory effects of salmeterol. 
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Introduction 
Asthma is considered to be an inflammatory disease of the 
airways, and exacerbations of asthma are usually associated 
with worsening of the underlying inflammation (1,2). In 
addition, chronic inflammation may eventually lead to 
thickening and fibrosis of the airway wall (airway remodel- 
ling), which can in turn cause reduced distensibility or fixed 
obstruction (3-7). Thus, current asthma treatment regimens 
are designed to modify the disease process by suppressing 
inflammation as well as providing relief from symptoms. 
The anti-inflammatory effects of inhaled corticosteroids 
(ICS) such as fluticasone propionate (FP) are well 
established. Inhaled FP in a broad range of dosages has 
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been shown to combine high topical potency with low 
systemic activity (8,9). From a clinical point of view, ICS 
may have a long-term disease-modifying effect and protect 
against fatal attacks by suppressing airway inflammation, 
as well as providing improvements in lung function and 
airway reactivity (10). International guidelines therefore 
recommend the introduction of regular, low-dose ICS in the 
early stages of asthma (11). However, some patients may be 
inadequately controlled by low-dose ICS alone, and the 
next step in treatment is either to increase the dose of ICS 
or add a long-acting &agonist (LABA) such as salmeterol 
or formoterol (1). At present, there is some debate over 
which of these options is preferable; however, several 
studies have shown that addition of a LABA to the existing 
dose of ICS improves symptom control and lung function 
to a greater extent than increasing the ICS dose (12-15). 
The clinical benefits of combining salmeterol and ICS 
raise the question of whether salmeterol can, independently 
of its long-lasting bronchodilator and functional antagonist 
effects, add to or complement the anti-inflammatory 
activity of ICS in asthma. Two studies have now addressed 
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this question, using bronchial biopsy and bronchoalveolar 
lavage (BAL) to obtain direct information on changes in 
airway inflammation during treatment. These studies are 
reviewed here. 
Bronchial biopsy/BAL studies 
Changes in various cellular markers and mediators of 
inflammation have been investigated in bronchial biopsies 
and BAL fluid obtained from over 100 asthmatic patients 
who participated in two randomized, double-blind, paral- 
lel-group studies (16-19). Both studies were conducted in 
patients with stable but symptomatic asthma who had been 
using the same dose of ICS [either beclomethasone 
dipropionate (BDP), budesonide or FP] for up to 12 
months, i.e. patients for whom ‘step 3’ treatment (11) would 
be recommended. The studies were also designed so that 
any improvement or worsening of airway inflammation 
caused by salmeterol could be detected. Both studies 
comprised a 2-week run-in period, during which patients 
had to exhibit incomplete symptom control despite 
continuing their existing ICS, and a 12-week treatment 
period during which they were randomized to receive either 
ICS alone (at low or high dose) or salmeterol plus low-dose 
ICS, as outlined in Table 1. Bronchial biopsies and BAL 
were performed at randomization and after completing 
treatment, in line with current safety guidelines (20). 
SALMETEROLANDFLUTICASONEINAIRWAYINFLAMMATION S27 
BRONCHIAL BIOPSY RESULTS 
In the first study, baseline biopsies from 40 patients showed 
similar numbers of mast cells, macrophages and total and 
activated T-lymphocytes to those in 11 non-asthmatic 
controls (17). However, total and activated eosinophil 
counts (as detected by EGl+ and EG2+ cell markers, 
respectively) were elevated. In this study, all patients 
continued taking their ICS treatment at the same dosage 
as during the run-in period; in addition, they were 
randomized to receive twice daily treatment with either 
FP 1OOpg (‘high-dose ICS’), salmeterol 50 pg (SALM/ICS), 
or placebo (‘low-dose ICS’) (Table 1). After treatment, 
numbers of EGl + eosinophils were significantly reduced 
from baseline in the SALM/ICS group but not in the other 
two groups (Fig. 1). There were no significant reductions in 
numbers of any other cell types. However, patients in both 
the SALM/ICS and high-dose ICS groups showed a trend 
towards a decrease in EG2+ eosinophils, compared with 
the low-dose ICS group (17). These contrasting results may 
reflect a difference in sensitivity of eosinophils to cortic- 
osteroid treatment, as the pre-study ICS treatment might 
already have minimized the numbers of corticosteroid- 
sensitive EGI + cells. Thus, the remaining EGl + eosino- 
phils would be relatively resistant even to large doses of 
corticosteroids (21). The additional effects of salmeterol on 
eosinophils indicate that it may increase their corticoster- 
oid-sensitivity or may act via an independent pathway. 
Indeed, salmeterol has previously been shown to potentiate 
TABLE 1. Entry criteria, treatment regimens and assessment schedules used in parallel-group bronchial biopsy/BAL studies 
First study (n=45) Second study (n = 56) 
[Ward et al. 1998 (16); Li et ~2. 1999 (17)] [Sue-Chu et al. 1999 (18); Wilson et al. 2000 
(191 
Enrolment Age 20-70 years; non-smoker; no acute Non-smoker; FEVi > 50% of predicted; 
respiratory tract infection, change in reversibility or BHR to methacholine 
asthma medication or hospitalization (PC20G8mg) 
for asthma within the previous 4 weeks; 
FEVi 3 60% of predicted normal 
value 
Run-in period (2 weeks) BDP or BUD lo&500 pg day-’ BDP or BUD 800-1200 ,ngdayy ‘, or FP 
400-5OOpg day-’ 
Symptom score > 2, rescue &agonist Daytime symptoms or rescue P2-agonist 
treatment and/or > 15% diurnal variation treatment on > 6 days, or nocturnal symptoms 
in PEF on > 7 days or >20% diurnal variation in PEF on 
>4 days 
Randomization Bronchial biopsy and BAL collection PCZo to methacholine and bronchial biopsy 
Treatment period (12 weeks): 
Low-dose ICS Maintain existing ICS, add placebo Change to FP 200,1~g bd 
High-dose ICS Maintain existing ICS, and FP 100,ug bd Change to FP 5OOpg bd 
Additional salmeterol Maintain existing ICS, add salmeterol Change to salmeterol 50 pg bd plus FP 
5Opg bd 2OOpg bd 
Post-treatment Bronchial biopsy and BAL collection PCZo to methacholine and bronchial biopsy. 
BAL, bronchoalveolar lavage; BDP, beclomethasone dipropionate; BHR, bronchial hyperreactivity; BUD, budesonide; 
FEV1, forced expiratory volume in 1 set; FP, fluticasone propionate: ICS, inhaled corticosteroid; PC20, concentration 
required to provoke a 20% decrease in FEVi; PEF, peak expiratory flow. 
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FIG. 1. Individual changes in total eosinophil numbers 
(EGI ‘) in the lamina propria determined by bronchial 
biopsy of asthmatic patients receiving low-dose ICS 
therapy and in addition (Twice daily): placebo, salmeterol 
5Opg or fluticasone propionate (FP) 1OOflg. Cell counts 
for non-asthmatic controls are also shown. *P= 0.01 for 
mean difference between pre- and posttreatment values. 
[Reproduced from (17) with permission.] 
the pro-apoptotic effects of corticosteroids on eosinophils 
(22). 
In the second study, patients were switched from their 
existing ICS (BDP or budesonide 80&12OO~g) to twice- 
daily treatment with either FP 200,~g (FP 200 group), 
500,ng (FP 500 group) or salmeterol 5Opg plus FP 2OOpg 
(SALM/FP) (Table 1) (18). The baseline biopsies in this 
study showed that run-in ICS treatment had already 
reduced activated eosinophil numbers in all patients, and 
that the possibility of study treatments decreasing them 
further was negligible. Numbers of submucosal mast cells in 
post-treatment biopsies were significantly lower than base- 
line in patients receiving SALM/FP. Although a significant 
increase in total (CD3+) and helper/inducer (CD4+) 
T-lymphocytes was observed in the FP 200 group, numbers 
of these cells were unchanged in the other two groups; in 
addition, treatment with SALM/FP resulted in a reduction 
in the expression of IL-4 and vascular cell adhesion 
molecule (VCAM)- 1 (19). 
BAL RESULTS 
BAL fluid analysis reflects events occurring on the airway 
surface, and can be used to detect soluble mediators of 
inflammation. Since BAL allows small airways to be 
sampled as well as large ones, the information gathered 
may complement that provided by biopsies (20,23). 
It has been suggested that mucosal oedema consequent to 
vascular proliferation may narrow the airway, possibly by 
increasing smooth muscle tone (7,27), and a bronchial 
biopsy study has demonstrated that the mucosal lamina 
propria contains substantially more blood vessels in 
asthmatic patients than in non-asthmatic controls (28). 
An increase in mucosal blood vessels may therefore reflect 
airway wall remodelling. ICS have recently been shown to 
reduce both the number of vessels and the area of the 
lamina propria that they occupy in asthmatic patients, in a 
dose-dependent manner (29). 
Compared with non-asthmatic controls, baseline BAL In a subsequent biopsy study in 34 asthma patients 
samples from 45 asthma patients in the Li et al. study receiving low-dose ICS treatment who were given supple- 
showed an ‘asthmatic signal’, including significantly higher mentary twice daily treatment with either salmeterol 50,~g 
counts of lymphocytes and eosinophils (17). The neutrophil or FP 1OOpg (30), the number of vessels in the lamina 
count was not elevated at baseline. However, consistent propria was significantly reduced by treatment with ICS 
with previous reports (24,25), the number of neutrophils in plus salmeterol and not with ICS plus FP; indeed, addition 
BAL from patients receiving high-dose ICS increased of salmeterol to ICS resulted in a normalization of vessel 
significantly from baseline (from 1.4 to 3.3%; P= O.OOl), number to the value observed in 25 non-asthmatic controls 
whereas there was a trend towards a decrease in the SALM/ (Fig. 2) suggesting that salmeterol may be able to influence 
ICS group (from 2.1 to 1.6%) (16). In addition, long-term airway remodelling by reducing the vascularity of 
concentrations of IL-8 a neutrophil chemoattractant, were the airway mucosa (30). 
unchanged in the high-dose ICS group but fell significantly 
in the SALM/ICS group (16). In contrast, high-dose ICS 
significantly reduced the expression of the HLA-DR 
marker (P = 0.05) of CD4+ T-lymphocyte activation, with 
a trend towards a decrease in expression of the CD25 
marker. These changes were not seen in the SALM/ICS 
group (17). 
Taken together, the results of these bronchial biopsy and 
BAL studies indicate that the combination of a LABA and 
low-dose ICS therapy reduces the number of several types 
of pro-inflammatory cell in the airways, and reduces the 
production of various mediators of inflammation and cell 
adhesion molecules. These effects are more pronounced 
with the combination therapy than with ICS alone, 
suggesting a complementary anti-inflammatory effect. This 
concept is borne out by two recent studies. In the first (the 
FACET study), 1 year’s treatment with formoterol 12pg 
plus budesonide 400 ,ug produced a greater reduction of the 
number of exacerbations than budesonide alone in patients 
with asthma symptoms despite ICS therapy (14); in the 
second, patients who received salmeterol plus low-dose FP 
for 24 weeks showed a trend towards fewer exacerbations 
than those on high-dose FP (15). Furthermore, in a recent 
l-year study in patients with moderate asthma, no 
significant changes in inflammatory cells and markers in 
induced sputum were found after twice daily treatment with 
either formoterol 12 pg/budesonide 100 pg or budesonide 
400yg alone (26), demonstrating that addition of a LABA 
to ICS therapy does not mask an increase in airway 
inflammation. 
REMODELLING OF AIRWAY 
VASCULATURE 
Remodelling of the airway wall over time is considered to 
be an important cause of reduced wall distensibility in mild 
asthma and fixed obstruction in more severe disease (3-7). 
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FIG. 2. Changes in airway wall vascularity after addition 
of salmeterol 50,ug twice daily to low-dose inhaled 
corticosteroid treatment for 3 months in 34 asthmatic 
patients. Values (mean +_ SEM) also shown for 25 untreated 
non-asthmatic subjects. 
Possible mechanisms 
Inflammation involves the influx into the bronchial wall of 
a variety of pro-inflammatory cells, which when activated 
induce the expression and release of a complex array of 
inflammatory mediators. Among the many chemotaxic 
cytokines for pro-inflammatory cells, IL-8, which is 
produced by macrophages, mast cells and epithelial cells 
on the airway surface (31-33), recruits predominantly 
neutrophils. Since IL-8 can also induce bronchial hyperre- 
sponsiveness in animals (34), it may play an important role 
in the pathogenesis of asthma. While the effects of ICS on 
IL-8 expression remain unclear, some studies have shown 
increased levels during treatment with corticosteroids 
(35,36). Similarly, IL-4 is a major inflammatory cytokine 
found in the airway; it has been shown to induce goblet cell 
production and secretion of mucin and mucous glycocon- 
jugates in an animal model and in human bronchial 
epithelial cells in vitro (37,38). In addition, epithelial, 
vascular and inflammatory cells produce a range of cell 
surface adhesion molecules which assist leucocyte infiltra- 
tion into the airway wall (39). Addition of salmeterol 50 pg 
twice daily to low-dose ICS therapy for 12 weeks reduced 
the levels of IL-8, IL-4 and VCAM-I in BAL samples from 
asthma patients (16,19), suggesting that prevention of 
cytokine or adhesion molecule expression may have been 
responsible for the reductions in leucocyte numbers 
recorded in that study. 
With respect to the potential effects of salmeterol on 
long-term airway remodelling, the enhanced vascularity of 
the airway mucosa may stem from elevated levels of 
angiogenic growth factors, which include IL-8 (4042). In 
contrast with FP, salmeterol reduced both the vascularity 
of the lamina propria (30) and IL-8 levels in BAL samples 
in asthmatic patients (16), suggesting a possible connection 
between the two. Salmeterol may also be able to modulate 
smooth muscle proliferation: in an in vitro model, it 
inhibited thrombin-stimulated hyperplasia of human air- 
way smooth muscle and reduced the concentration of the 
regulatory protein cyclin Dl, actions which were not 
mediated via /&receptors (43). Furthermore, reactive 
oxygen species generated by activated neutrophils are 
known to be involved in the inflammatory processes that 
lead to fibrosis and airway remodelling in chronic 
obstructive pulmonary disease and obliterative bronchioli- 
tis after lung transplantation (44,45), and may play a role in 
airway inflammation in asthma (44,46). 
The actual mechanisms underlying all the effects exerted 
by salmeterol remain unclear. However, most types of cell 
can express &receptors, and prolonged stimulation of 
these receptors might influence some of the pathways 
leading to airway inflammation in asthma. Animal studies 
have shown that /&-receptor stimulation by salmeterol can 
prevent platelet activating factor-induced adhesion of 
leucocytes to mucosal blood vessels (47) and eosinophil 
accumulation in the airway lumen (48). Furthermore, 
glucocorticoids have been shown to induce the expression 
of &receptor mRNA, prevent Pz-agonist-induced down- 
regulation of /&receptors, and increase the number and 
function of &receptors in human respiratory tissue (49- 
51). These may help to explain the additional anti- 
inflammatory effects seen when salmeterol is combined 
with ICS. 
Conclusions 
Recent bronchial biopsy and BAL studies have demon- 
strated that treatment with a combination of salmeterol and 
ICS produces independent or additional reductions in 
several pro-inflammatory cells, cytokines and cell adhesion 
molecules compared with ICS alone. There may also be an 
independent inhibitory effect of salmeterol on angiogenesis 
in asthma patients treated with ICS. Some of these effects 
may explain the improved control of asthma symptoms 
observed when salmeterol is added to low-dose ICS 
therapy, and may help to modify the long-term sequelae 
of asthma. 
These findings importantly indicate that salmeterol does 
not have a pro-inflammatory effect or mask persistent 
airway inflammation in the presence of ICS. There is 
encouraging evidence of a complementary interaction 
between salmeterol and FP which results in enhanced 
anti-inflammatory activity. More studies are needed to 
determine why this occurs, and what the clinical implica- 
tions of the interaction may be. 
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